Identification and Validation of P311 as a Glioblastoma Invasion Gene Using Laser Capture Microdissection

Luigi Mariani, Wendy S. McDonough, Dominique B. Hoelzinger, Christian Beaudry, Elzbieta Kaczmarek, Stephen W. Coons, Alf Giese, Mojdeh Moghaddam, Rolf W. Seiler, and Michael E. Berens

Neurooncology Laboratory [L. M., W. S. M., D. B. H., C. B., E. K., M. E. B.], Department of Neuropathology [S. W. C.], Barrow Neurological Institute, Phoenix, Arizona 85013; Neurochirurgische Klinik, Universität-Krankenhaus Eppendorf, 20246 Hamburg, Germany [A. G.]; National Human Genome Research Institute, NIH, Bethesda, Maryland 20892 [M. M.]; and University Hospital, Inselspital, 3010 Bern, Switzerland [R. W. S.]

ABSTRACT

The mRNA expression profiles from glioblastoma cells residing at the tumor core and invasive rim of a human tumor resection were compared. From a single tumor specimen, 20,000 single cells from each region were collected by laser capture microdissection. Differential expression of 50–60 cDNA bands was detected. One of the sequences overexpressed by the invasive cells showed 99% homology to the P311 gene, the protein product of which is reported to localize at focal adhesions. Relative overexpression of P311 by invading glioblastoma cells compared with tumor core was confirmed by quantitative reverse transcription-PCR of six glioblastoma specimens after laser capture microdissection collection of rim and core cells. In vitro studies using antisense oligodeoxynucleotides and integrin activation confirmed the role of P311 in supporting migration of malignant glioma cells. Immunohistochemistry studies confirmed the presence of the P311 protein in tumor cells, particularly at the invasive edge of human glioblastoma specimens.

INTRODUCTION

Failure in surgical cure of malignant gliomas is mainly due to those tumor cells that have invaded the normal brain far beyond the resectable areas (1–3). These remaining cells also resist radio- and chemotherapy and eventually lead to tumor regrowth and the patient’s demise within <1 year from diagnosis (4–6). The identification of the mechanisms used by glioma cells to invade the brain could potentially indicate therapeutic strategies to reduce further spreading and/or to target the invading cells more specifically.

Investigations of tumor cell motility in general, and glioma invasion in particular, are mainly addressed using in vitro strategies. Such efforts led to the discovery and characterization of a significant number of molecules involved in glioma migration and potentially glioma invasion (7–12). However, in vitro strategies have some important limitations. One of these is the failure to reproduce the cerebral environment, which is likely to represent a unique determinant for the invading glioma cells.

To elucidate the mechanisms of glioma invasion in vivo, we coupled the capacity of LCM\(^2\) to harvest single glioblastoma cells residing in the tumor core and at the invading edge with classical gene discovery techniques such as mRNA differential display and QRT-PCR (13). We were able to identify a number of known and unknown gene candidates potentially involved in glioma invasion. In this ongoing effort, we confirmed a role in glioma migration in vitro for one of these first gene candidates, the protein P311.

MATERIALS AND METHODS

LCM

Cryopreserved glioblastoma specimens from seven patients were cut in serial 6–8-μm sections and mounted on uncoated slides treated with diethyl pyrocarbonate. The tumor core and adjacent invasive rim were identified on a coverslipped H&E-stained section (Fig. 1). One specimen was selected for collection of 20,000 individual cells for mRNA isolation and differential display analysis; the other specimens were used for quantitative, differential RT-PCR analysis. Cryostat sections intended for LCM were transferred from −80°C storage and immediately immersed in 75% ethanol at RT for 30 s. Slides were rinsed in H₂O, stained with filtered Meyer’s hematoxylin for 30 s, rinsed in H₂O, stained with bluing reagent for 20–30 s, washed in 70 and 95% ethanol for 1 min each, stained with cosin Y for 20–30 s, dehydrated in 95% ethanol (twice for 1 min each), 100% ethanol (stored over molecular sieve; three times for 1 min each) and Xylene (three times for 10 min each). Slides were air dried under a laminar flow for 10–30 min and immediately processed for LCM. Diethyl pyrocarbonate-treated, autoclaved, distilled water was used to prepare every solution.

LCM was performed with a PixCell II Microscope (Arcturus Engineering, Inc., Mountain View, CA) using a 7.5-μm laser beam at 50–100 mV. Cells in the tumor core were readily identified and captured; tumor cells immediately adjacent to necrotic areas, cortical areas, or cells with a small regular nucleus, endotheial cells, and blood cells were avoided. Neoplastic astrocytes in the invasive rim −1 cm from the edge of the tumor core were identified according to the criteria of nuclear atypia (coarse chromatin, nuclear pleomorphism, multinucleation) and, whenever possible, according to nuclear and/or cytoplasmic similarity with the glioblastoma cells in the core.

Differential Display of mRNA

Total RNA was isolated from the LCM-collected samples using StrataPrep (Stratagene) according to manufacturer’s directions. Generation of cDNA segments and amplification of these pieces by PCR was done as previously described (14). Briefly, 100 ng of total RNA from each population were added to duplicate reactions, each containing the H-T₁₅ oligo(dT) primer anchored to the beginning of the poly(A) tail. RT-PCR was used to synthesize random primed segments of cDNA per manufacturer’s directions (GeneHunter RNAimage, Nashville, TN). Each RT mix was aliquoted, combined with one of eight different AP primers, and tagged with \(^{32}P\)dATP. A display of the cDNAs was generated in the form of bands on a 6% polyacrylamide-urea gel (Fig. 2). Reproducible bands that were differentially expressed in either of the cell populations were excised from the gel, reamplified using the appropriate matching AP primer and H-T₁₅ primer from the RNA image kit, then cloned using a TA Cloning Kit (Invitrogen, San Diego, CA). Bacterial colonies were plated on agar containing 50 μg/ml ampicillin and 40 μl of 40 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside. Colonies carrying the plasmids with inserts (white) were harvested, expanded, verified using EcoRI restriction digestion, and sequenced using a CEQ2000 automated sequencer (Beckman). From these candidates, a band of interest, a 318-bp sequence with 99% homology (302 of 305 bp) to P311 was elected for in-depth analysis.

QRT-PCR

Quantification. Real-time quantitative PCR was performed using the LightCycler (Roche) with fluorescence signal detection (SYBB green) after each cycle of amplification. Quantification was focused on the initial exponential phase of
amplification above baseline according to the LightCycler software (15–17) and as described recently (13, 18). The calculated cDNA copy number in each sample was derived from an extrapolated crossing point of a mathematically derived line extending from the exponential phase of amplification in a plot of fluorescence intensity (SYBR green) versus cycle number. For each reaction, diluted amounts of known templates provided quantitative standard curve reactions and for each gene of interest from which cDNA copy number in clinical samples could be determined. Histone H3.3 was used as a housekeeping gene to normalize the initial content of total cDNA in the samples. The relative expression ratio between the invasive rim and the tumor core (rim:core ratio, $R$) was calculated as $R = \frac{X}{Y}$, where $X$ = P311 copy number in the rim and $Y$ = P311 copy number in the core, both normalized to equivalent amounts of histone H3.3.

**PCR Conditions and Reagents.** Total RNA was isolated from LCM-collected cells or cultured glioma cells using StratePrep. Primer sequences for P311: sense 5'-GACTGACTTCTCTGTTTCTT-3', antisense 5'-CTTACCAGCTTGCGTATTTATGACT-3' (amplicon size, 278 bp). PCR conditions for P311: 95°C for 30 s, 70°C for 7 s, 72°C for 20 s, 40 cycles, followed by the melting curve analysis. Primers for histone H3.3: sense 5'-CCACTGAACTCTGATTCCGC-3', antisense 5'-GGGTGCTAGCTGGATGTTTCT-3' (amplicon size, 215 bp). PCR conditions for histone H3.3: 95°C for 30 s, 64°C for 6 s, 72°C for 20 s, 40 cycles. Reference template standards for quantitative analysis of the genes of interest were prepared by cloning the P311 and histone H3.3 cDNA sequences into pCR 2.1 TOPO TA vector (Invitrogen). After expansion in *Escherichia coli*, plasmids were extracted and linearized, and the concentration of DNA was determined by absorption at 260 nm. PCR was performed on 2 μl of cDNA in a final volume of 20 μl. Analysis of the melting curves (standards versus sample and negative control) ensured specificity of the amplification for the expected product (15). Additionally, agarose gel electrophoresis of the PCR products, followed by staining with ethidium bromide, was performed to confirm the specificity of the amplification.

**Induction of Migration on Cell-derived ECM and Expression of P311**

To create a coating of cell-derived ECM proteins, T25 culture flasks were seeded with SF767 glioma cells (19, 20). These were grown in MEM supplemented with 10% FBS to postconfluence and then removed by treatment with
Technologies, Inc.) (20°FBS. Cells were treated either with liposomes only (Lipofectin reagent; Life grown to 30–40% confluence in T25 flasks in MEM supplemented with 10% CTAAGGCTT-3'. SF767, U251 MG, and U118 MG glioma cell lines were 9P311 mRNA as follows: antisense ODN 5'-AAATGGTTCTTGACT-

Antisense Treatment and Migration Assays

About 2000–3000 SF767 and T98G glioma cells were seeded through a cell sedimentation manifold (see "Antisense Treatment and Migration Assays") on 10-well slides coated with either 1% BSA or human laminin (10 μg/ml). After 24–48 h, the cells were fixed with 2% paraformaldehyde for 10 min and then processed for P311 staining or mouse antivinulin (1:400, Sigma Chemical Co.) as described above. Negative controls were stained with a 1:50 dilution of preimmunization rabbit sera. Finally, the cells were incubated for 30 min with 1:100 dilution of FITC-conjugated antirabbit antibody or rhodamine-conjugated anti-mouse antibody (both from Roche Molecular Biochemicals). Images were collected using a Zeiss Axioplan fluorescence microscope (Zeiss, New York, NY) with filter sets 9 and 14, respectively.

Laser Scanning Cytometry

Laser scanning cytometry was used to quantitatively assess decreased levels of P311 protein during the migration assay after antisense treatment (Fig. 7B). After P311 immuno-fluorescent staining of the migration assays, the slides were analyzed using a laser scanning cytometer (CompuCyte, Cambridge, MA), which allows quantitative fluorescence signal processing of individual cells in a population on a flat surface. The laser scanner cytometer records the FITC fluorescence of each single cells on the well and counts the total number of cells on the well. The mean peak fluorescence of all of the cells in each well is calculated. The average of five wells was compared among untreated controls and the different treatments (Lipofectin only, antisense or mismatched ODNs). Briefly, cells were grown to 60% confluency before treatment with either liposomes only or in combination with 2.5 μM antisense, 2.5 μM sense, or 2.5 μM random oligonucleotides. After 4 h of treatment, 4000 cells of each population were seeded in quadruplicate wells of three 96-well flat-bottomed plates in 200 μl of culture medium supplemented with 10% FBS. The plates were incubated for 4, 20, and 32 h, respectively. Alamar blue was added in a volume of 20 μl (10% of total volume) to the cells at the various time points and incubated for 2 h. The plates were read on a fluorescence plate reader (excitation 530 nm; emission 590 nm). Averages of the fluorescent signals were calculated and plotted against a standard curve of untreated cells to assess live cell number.

Statistical Analysis

A two-tailed, unpaired t test compared the log10 value of ratios of gene expression. Differences between invasive rim and tumor core (R/C Ratio) were analyzed relative to the null hypothesis, which predicted a ratio of 1 (log10 ratio, 0).

RESULTS

Overexpression of P311 by the Invasive Tumor Cells in Vivo.

Discreet cDNA bands differentially expressed using the primer set H-T11A and H-AP2 (clone R.2.1) were consistently identified in the tumor core (C) and the invasive rim (R) using LCM. Samples were processed for RNA isolation, followed by QRT-PCR for histone H3.3 (housekeeping gene for normalization) and P311 (gene of interest). Melting curve analysis and agarose gel electrophoresis were used to verify amplicon purity and not to quantify the PCR product.
in the context of embryonic neuronal migration (24) and of MetHGF/SF signaling in SK-LMS cells (a leiomyosarcoma cell line) (21). P311 is a 2036-bp mRNA encoding a 68-amino acid polypeptide with a very short half-life. Rapid turnover of P311 is believed to be due to degradation by the proteasome-ubiquitin system and an unidentified metalloprotease (21).

Six glioma specimens were analyzed for relative levels of expression of P311 in cells at the tumor core and invasive rim. The ratio of P311 message template number (cDNA) in rim:core was almost invariably >1 in QRT-PCR analysis (Table 1); the mean R:C was 3.1 for the first round of analysis, RT1 (range ± SD 1.2–8.1) and 3.3 for the second round, RT2 (range ± SD 1.3–7.8). The log_{10} values of the ratios for each QRT-PCR were statistically different from the null hypothesis (R:C, 1) in the unpaired, two-tailed Student t test (P = 0.018 for RT1, P = 0.016 for RT2, P = 0.0006 for RT1 and RT2 combined).

To estimate the impact of a possible contamination of the “invasive rim” sample with normal brain cells, we compared the level of mRNA by QRT-PCR of samples from four normal brains (cortex and adjacent white matter retrieved within 2 h postmortem) and two glioblastomas. The level of P311 mRNA in the normal brain averaged 1.83-fold higher than in the two glioblastomas (range ± SD 1.38–2.53; P < 0.05). The LCM-harvested tumor cells show an average 3.25-fold overexpression of P311 in invasive cells compared with cells in the tumor core (range ± SD 1.3–8.1; P = 0.0006). Statistical comparison of these data sets indicates that the elevated expression of P311 in the rim samples compared with tumor core is not due to contamination by normal brain in the rim (P = 0.028).

Furthermore, from the analysis of other genes of known overexpression in brain tumor cells compared with normal brain, the cells captured in the invasive rim are predominantly tumor cells in our samples (data now shown). The presence of P311 mRNA in the adult brain has been described (24), but its role remains obscure.

Reduced Migration of Glioma Cells Treated with Antisense P311-ODNs. Expression of P311 in glioma cells is amenable to manipulation by treatment with antisense ODNs designed against the 3’ end of the P311 mRNA. Human glioma cell line SF767 showed specific reduction in P311 mRNA after treatment with antisense P311 ODN compared with treatment with mismatched or sense ODNs (Fig. 4A). Human glioma cells treated with 2.5 μM ODNs only inhibited migration if the sequence was complimentary to P311 (antisense; Fig. 4B). Migration inhibition occurred whether the cells were plated on a specific substrate (laminin) or a nonspecific substrate (coating with BSA). The magnitude of inhibition was dependent on the concentration of antisense P311 ODNs (Fig. 5A). Quantitative immunofluorescence of P311 protein in SF767 glioma cells treated with antisense P311 ODNs demonstrates loss of the P311 translation product (Fig. 5B). In a monolayer migration assay, a marked dose-dependent decrease in the migration rate of SF767 cells on laminin substrate was evident (Fig. 5C). The morphology of the anti-P311 ODN-treated cells showed a marked decrease in the number of lamellipodia, resulting in a rounded or pilocytic rather than a polygonal shape compared with the controls (data not shown). The viability assays did not reveal any toxic effect due to the antisense P311 ODNs compared with the random or sense ODN sequences (data not shown).

Overexpression of P311 in Cells Activated to Migrate. Human glioma cell lines G112 and T98G were grown either in standard culture flasks or in flasks precoated with glioma-derived ECM. This coating enhances the motility behavior of these cells (25–27). Total RNA was isolated from these two cell populations for quantitative RT-PCR analysis of P311 expression on replicate experiments. Culture of both glioma cell lines on motility-promoting substrate resulted in a significant overexpression of P311 compared with the control in replicate experiments. For G112 cells, overexpression on ECM was 1.63-fold (range within 1 SD 1.05–2.52; P = 0.015) in one experiment, and 52-fold (range within 1 SD 28.9–93.6; P = 0.02) in a second. T98G cells on ECM overexpressed P311 mRNA by 7.5-fold (range within 1 SD 1.6–23.1; P = 0.21).

Immunochemical Localization of the P311 Protein in Frozen Sections of Glioblastoma Specimens and Glioma Cell Lines. Peroxidase-based immunohistochemistry studies on frozen sections of specimens 15 and 16 show a strong P311 staining confined to the

**Table 1. Overexpression of P311 in invasive cells versus tumor core from human glioblastoma specimens**

Overexpression of the P311 mRNA in invasive glioblastoma cells captured using LCM is expressed as a R:C ratio for six human specimens analyzed by quantitative RT-PCR in duplicate reactions (RT1 and RT2). The ratios are significantly higher than 1 in both RT reactions (P = 0.018 for RT1 and P = 0.016 for RT2; see “Materials and Methods” for statistical analysis).

<table>
<thead>
<tr>
<th>Specimen</th>
<th>RT1</th>
<th>RT2</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>3.14, 1.55*</td>
<td>1.95</td>
</tr>
<tr>
<td>6</td>
<td>3.52</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>19.4, 3.06*</td>
<td>1.9</td>
</tr>
<tr>
<td>15</td>
<td>3.2</td>
<td>7.4</td>
</tr>
<tr>
<td>17</td>
<td>0.85</td>
<td>4.7</td>
</tr>
<tr>
<td>Mean</td>
<td>3.1</td>
<td>3.3</td>
</tr>
<tr>
<td>Range (± SD)</td>
<td>1.2–8.1</td>
<td>1.3–7.8</td>
</tr>
</tbody>
</table>

* Repeat PCR run.
cytoplasm of tumor cells in the core and at the invasive rim (Fig. 6). Individual cell staining is possibly stronger in tumor cells of the invasive rim; however, the potential intermingling of normal and reactive glial cells as well as neurons prevents unequivocal assessment of a quantitative labeling index for P311 at the invasive edge. P311 immunoreactivity was very low in the normal brain parenchyma (regions without obvious tumor infiltration).

Immunofluorescent staining of human glioma cell lines SF767 and T98G seeded on a migration-activating substrate of laminin, indicates a cytoplasmic localization of P311. Topographic projection of the confocal images illustrates that the nuclei of these cells are devoid of P311 immunoreactivity (data not shown). Simultaneous immunofluorescent staining of these cells for P311 and vinculin did not demonstrate definite colocalization at the focal adhesions (Fig. 7), a feature described by Taylor et al. (21) in normal human astrocytes in culture using the same reagents.

**DISCUSSION**

Improved understanding of the mechanisms used by glioma cells to invade the surrounding brain tissue is limited by the inability to reproduce this cerebral environment *in vitro*. In this study, we try to identify the genetic programs activated by glioma cells caught in the act of invading the brain tissue *in vivo*. We have used the capacity of LCM to harvest single cells from frozen sections coupled with differential display analysis of mRNAs isolated from the invading and noninvading tumor cells. A major potential impediment to successful use of LCM at the invasive edge of a glioblastoma specimen is due to the difficulty to reliably identify tumor cells, requiring their differentiation from normal/reactive astrocytes and other glial or neuronal cells on a frozen section (28, 29). This difficulty progressively increases the further away from the tumor edge into the normal parenchyma cell collection is.

**Specimen #15**

**Specimen #16**

Fig. 5. Dose-dependent effects of P311 antisense ODN treatment on P311 mRNA and protein levels and migration rates of glioblastoma cells. In A, the number of P311 mRNA copies (assessed by QRT-PCR) decreased after treatment with increasing doses of antisense P311 ODNs. In B, quantitative analysis by laser scanning cytometry of cells immunostained for P311 also showed an inverse relationship between the level of P311 protein and the dose of antisense ODNs. Fluorescence intensities for each individual cell of the well containing a migration assay were recorded. The mean peak fluorescence of the cell population on the well was calculated. The average of five replicates (wells) is shown. The error bars within 1 SD are hidden by the triangular symbols. The controls (liposomes only and mismatched ODNs) did not show any reduction in P311 protein levels (not shown). In C, in parallel, the migration rate of SF767 glioma cells on laminin 10 μg/ml decreased in a dose-dependent manner after P311 antisense treatment compared with the controls. Bars, 1 SD from the mean of five replicates. This experiment was repeated twice with similar results.

Fig. 6. Immunohistochemistry studies for P311 in glioblastoma specimens. Peroxidase-based immunostaining for P311 in frozen sections of specimens 15 and 16. **A** and **B**, tumor cells with positive, cytoplasmic P311 immunostaining in the tumor core and in the infiltration zone, respectively. **C**, immunostaining with preimmune serum. **D**, immunostaining with antisense ODN treatment compared with the controls. Bars, 1 SD from the mean of five replicates. This experiment was repeated twice with similar results.

EX VIVO DISCOVERY OF P311 AS A GLIOMA INVASION GENE
adhesions (a feature described by Taylor arrows). Colocalization of vinculin and P311 at the focal adhesions shows diffuse, punctate cytoplasmic staining in A. Localization of vinculin and P311 at the focal adhesions (arrows; a feature described by Taylor et al. in Ref. 21 in normal human astrocytes in culture) could not be demonstrated in T98G cells.

Fig. 7. P311-immunofluorescence in glioma cells. T98G glioma cells migrating on a laminin substrate were stained using rabbit anti-P311 (A) and mouse antivinculin primary antibodies (B), followed by fluorescein-conjugated antirabbit and rhodamine-conjugated antimouse secondary antibodies, respectively. P311 immunofluorescence shows diffuse, punctate cytoplasmic staining in A. Colocalization of vinculin and P311 at the focal adhesions (arrows; a feature described by Taylor et al. in Ref. 21 in normal human astrocytes in culture) could not be demonstrated in T98G cells.

attempted. Retrieving single tumor cells from a frank glioblastoma by LCM is a straightforward procedure as opposed to capturing tumor cells from the invasive tumoral edge, which is time consuming and requires a sound interpretation of histopathology. The main potential caveat of this procedure is the risk of capturing normal brain cells. To reduce this risk, we captured cells in the immediate vicinity of the tumoral edge in the white matter. We selected cells with dysplastic nuclei and cells similar to those in the frank tumor tissue. The isolated RNA was of sufficient quality to perform differential display and quantitative RT-PCR for validation in additional human samples.

LCM of a cryopreserved glioblastoma specimen followed by mRNA differential display was successful in identifying gene candidates implicated in the invasion process. The differential display analysis showed that the vast majority of mRNAs (~800 fragments) were expressed at approximately the same level by the two cell populations. Against this background of homogeneity, 50–60 differentially expressed cDNA fragments were isolated, cloned, and sequenced. We initially selected a band corresponding to a fragment of the coding sequence of P311 for in-depth investigation. Quantitative RT-PCR analysis of additional glioblastoma specimens confirmed overexpression of this gene in the invasive glioma cells harvested by LCM (Table 1).

The first of the three open reading frames of the P311 cDNA is well conserved among different species (human, mouse, chicken) and encodes a 68-amino acid polypeptide. Such conservation argues for a fundamental function of the gene product.

P311 was first described by Studler et al. (24) as a transcript abundantly expressed by neuronal cells in the striatum and superficial cortical layers during gestational days 17–20. The authors concluded that this gene is overexpressed by neurons belonging to the late migration wave from the germinal to the cortical layers. They further described the persistence of this transcript in the cerebellar cortex, hippocampus, and olfactory bulb in the mouse. Because a high neuronal plasticity is known to occur in these locations, the authors hypothesized a role for P311 in this context. Taylor et al. (21) recently found that P311 is highly expressed by human intestinal smooth cells, normal human astrocytes in culture, and the leiomyosarcoma cell line SK-LMS. Expression of P311 was reduced in the SK-LMS cell line when cells were modified to have a high c-Met-HGF/SF signaling which can induce motility, invasiveness and angiogenesis (30–32). Neural precursor cells induced to terminally differentiate by NGF treatment also showed a reduction in P311 expression (21). However, single doses of HGF/SF did not result in a reduced mRNA expression of P311 by the SK-LMS cell line.

Our finding of elevated P311 expression in invading glioblastoma cells relative to cells in the same tumor residing in the (noninvading) tumor core align with a putative role of this gene product in invasion, or possibly transient dedifferentiation to a more motile phenotype. The antisense ODN experiments argue that specific down-regulation of P311 mRNA and protein levels suppresses migration. These findings accumulate to suggest that P311 expression may be elevated to achieve portions of the invasive cascade of these malignant cells. The immunohistochemical staining of the human glioblastoma specimens confirmed the presence of the P311 protein in the cytoplasm of tumor cells in the tumor core and particularly at the tumor edge. The rarity, and potentially the absence, of normal brain cells staining positively for P311 indicate that this protein is mainly produced by tumor cells and not by normal or reactive brain cells in the surrounding parenchyma. These findings argue for a null expression of P311 protein by normal astrocytes, although Taylor et al. (21) indicated that cultured astrocytes express P311 messenger. Manipulation of human glioma cell migration behavior by culture on motility-enhancing substrates showed elevation in P311 messenger. We speculate that P311 is a biochemical determinant of glial cell migration and/or invasion. Explanted normal astrocytes may manifest very active migratory behavior, which may explain the earlier report.

Mechanisms other than gene expression regulation may also impact the influence of P311 on glioma cell migration. These may include activation or suppression by phosphorylation, sequestration, or release of translated P311 gene product in response to signaling mediators in the cell, and reduced or increased degradation. A potential phosphorylation site at the COOH end of P311 indicates that this protein may be regulated by phosphorylation. The half-life of this protein appears to be very short due to proteasome and metalloprotease activity, below 5 min according to Taylor et al. (21).

Confocal microscopy studies indicated colocalization of the P311 protein with vinculin at the focal adhesion in normal human astrocytes in culture (21). Our studies demonstrate that when human glioma cells are cultured under migration-activated conditions, the localization of P311 is diffuse in the cytoplasm but not at the focal adhesions (Fig. 7). These findings suggest at least a putative role of P311 in glioma migration.

LCM allows capturing of circular areas surrounding nuclei without respecting cytoplasmic contours or cell membranes. Thus, we cannot exclude a possibility that the LCM-collected mRNA was actually sublocalized in the cytoplasmic periphery of normal brain cells as a response to the invading neoplastic cells. In this case, our findings would be suggestive of a reactive brain cell response to invading glioblastoma. The in vitro observations, however, refute this line of thinking because suppression of P311 expression retards glioma migration, and activation of migration up-regulates P311 expression in glioma cell lines.

Overall, our data suggest a specific role of P311 in activating glioma invasion through enhanced glioma cell motility. The absence of this protein in the focal adhesions (where it has been localized in
normal astrocytes in culture) along with its overexpression “in vivo” and “in vitro” during migration suggest a relocation and possibly a switch in function. Further studies are needed to assess the role of this protein and its potential interactions with the cytoskeleton or soluble mediators of migration.

The success of the strategy used in this study opens new perspectives for research in the field of glioma invasion. We anticipate that more accurate identification of tumor cells with a highly invasive phenotype in tissue sections will be possible in the near future. This ability, coupled with modern techniques to assess differential gene expression using minuscule amounts of RNA, may lead to a better understanding of the mechanisms responsible for the unique invasive behavior of glioma cells in vivo.

Acknowledgements

We thank George F. Vande Woude and Gregory A. Taylor for providing us with the P311 antibodies and Jim Borree from CompuCyte for generating the laser scanner cytometry data.

REFERENCES


Announcements

Meeting of the Radiation Research Society

The annual meeting of the Radiation Research Society will be held at the State University of Iowa, Iowa City, on June 22–24, 1953. The Society will be the guest of the University, and all meetings will be held on the campus. The program will consist of: (1) Two symposia, one on "The Effects of Radiation on Aqueous Solutions," which includes the following speakers: E. S. G. Barron, Edwin J. Hart, Warren Garrison, J. L. Magee, and A. O. Allen. The second is "Physical Measurements for Radiobiology" and companion talks by Ugo Fano, Burton J. Moyer, G. Failla, L. D. Marinelli, and Payne S. Harris. (2) On Monday night, June 22, a lecture by Dr. L. W. Alvarez on meson physics has been tentatively scheduled. On Tuesday night, June 23, Dr. L. H. Gray of the Hammersmith Hospital, London, will speak on a topic to be announced. Dr. Gray's lecture is sponsored by the Iowa Branch of the American Cancer Society. Those desiring to report original research in radiation effects, or interested in attending or desiring additional information, please contact the Secretary of the Society, Dr. A. Edelman, Biology Department, Brookhaven National Laboratory, Upton, L.I., New York.

Erratum

The following correction should be made in the article by Beck and Valentine, "The Aerobic Carbohydrate Metabolism of Leukocytes in Health and Leukemia. I. Glycolysis and Respiration," November, 1953, page 891; substitute for the last paragraph:

The data in Table 8 permit several interesting calculations. If one compares the amount of glucose actually disappearing with the sum of the amount equivalent to lactic acid produced plus that equivalent to O₂ consumption, it is seen that the amount of glucose "cleavage products" exceeds the amount of glucose utilized by 12 per cent in N and 27 per cent in CML and is exceeded by the glucose utilized by 16 per cent in CLL. If the assumption is made that, in this respect, the myeloid and lymphoid cells of leukemia are similar to those of normal blood, it may be that the computed normal figure represents a summation of the myeloid (M) and lymphoid (L) cells that make up the normal leukocyte population. Thus, if M = +0.27 and L = −0.16 and the normal differential is 65 per cent M and 35 per cent L, then

\[ 0.65 (+0.27) + 0.35 (-0.16) = +0.12 \]

a figure identical to the observed +0.12 for normal leukocytes.
Identification and Validation of \textit{P311} as a Glioblastoma Invasion Gene Using Laser Capture Microdissection

Luigi Mariani, Wendy S. McDonough, Dominique B. Hoelzinger, et al.


\begin{tabular}{|c|c|}
\hline
\textbf{Updated version} & Access the most recent version of this article at:  \\
& http://cancerres.aacrjournals.org/content/61/10/4190  \\
\hline
\textbf{Cited articles} & This article cites 29 articles, 5 of which you can access for free at:  \\
& http://cancerres.aacrjournals.org/content/61/10/4190.full.html#ref-list-1  \\
\textbf{Citing articles} & This article has been cited by 18 HighWire-hosted articles. Access the articles at:  \\
& /content/61/10/4190.full.html#related-urls  \\
\hline
\end{tabular}